FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP 1s BioSpace Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to weigh easing limits on unproven peptides August 11, 2025: The FDA voices concern about sites that supply compounding ingredients Partnership for Safe Medicines The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University